Autobio(603658) 平安证券·2025-04-18 07:16Investment Rating - The report maintains a "Recommended" rating for the company [1][9]. Core Views - The company achieved a slight increase in revenue for 2024, with total revenue of 4.471 billion yuan, up 0.62% year-on-year, while net profit attributable to shareholders was 1.194 billion yuan, down 1.89% year-on-year [4][5]. - The company faces multiple policy impacts in the domestic in vitro diagnostics industry, leading to a slowdown in revenue growth, which is expected to continue into Q1 2025 [5][9]. - The company has seen robust growth in its immune diagnostics and international markets, with international revenue increasing by 36.25% year-on-year [6][9]. Summary by Sections Financial Performance - In 2024, the company reported a revenue of 4.471 billion yuan and a net profit of 1.194 billion yuan. The revenue for Q1 2025 was 996 million yuan, down 8.56% year-on-year, with a net profit of 270 million yuan, down 16.76% year-on-year [4][5]. - The company’s gross margin for the year was 65.36%, with a stable overall expense ratio [5]. Business Segments - The immune diagnostics segment generated 2.556 billion yuan in revenue, up 2.91% year-on-year, while microbiological testing revenue was 361 million yuan, up 11.48% year-on-year. Molecular diagnostics revenue surged by 101.01% to 35 million yuan [6]. - The company has expanded its product offerings significantly, launching new series in various diagnostic fields, enhancing its brand influence [8]. Market Outlook - The report anticipates that the company will continue to leverage its extensive product line to capture market opportunities as policies evolve [6][9]. - The forecast for net profit attributable to shareholders for 2025-2027 is 1.295 billion yuan, 1.588 billion yuan, and 1.949 billion yuan, respectively, indicating a positive long-term growth outlook despite short-term pressures [9].